Floatz logo

177Lu-rhPSMA-10.1

Urogenital Neoplasms

Blue Earth Therapeutics LtdSmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

29 Active assets in the Urogenital Neoplasms cohort.

Asset / SponsorPhaseRating
NORMAL HUMAN SERUM ALBUMIN
Region Skane
Phase 4BB
Docetaxel
Sandy Srinivas
Phase 3BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Astellas Pharma Global Development, Inc.
Phase 2BB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Eli Lilly and Company
Phase 3B
VOLITINIB
AstraZeneca
Phase 3B

View all 50 →

Same molecule, other indications

177Lu-rhPSMA-10.1 is also rated in:

prostate disorderDormant
CCC
Indicative ·
48 / 100
View asset →
metastatic prostate carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
prostate neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →